Get our Free Patent Expiration Newsletter

Serving hundreds of leading biopharmaceutical companies globally:

Daiichi Sankyo
Federal Trade Commission
Johnson and Johnson
Chinese Patent Office

Generated: September 22, 2019

DrugPatentWatch Database Preview

Patent: 8,080,575

  Try a free trial

See Plans and Pricing

« Back to Dashboard

Summary for Patent: 8,080,575
Title:Gamma-lactam compounds for promoting bone growth
Abstract: The present invention provides compounds, compositions and methods for promoting bone growth. Compounds useful in the methods of the present invention include compounds of Formula I, wherein each R.sup.1 and R.sup.2 is H, halogen, C.sub.1-6 alkyl, C.sub.1-6 alkoxy, C.sub.1-6 haloalkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.1-6 haloalkoxy, --OR.sup.4, --NR.sup.4R.sup.5, --SR.sup.4, --C(O)R.sup.4, --C(O)OR.sup.4, --C(O)NR.sup.4R.sup.5, --N(R.sup.4)C(O)R.sup.5, --N(R.sup.4)C(O)OR.sup.5, --N(R.sup.4)C(O)NR.sup.4R.sup.5, --OP(O)(OR.sup.4).sub.2, --S(O).sub.2OR.sup.4, --S(O).sub.2NR.sup.4R.sup.5, --CN, cycloalkyl, heterocycloalkyl, aryl or heteroaryl. Each R.sup.4 and R.sup.5 is H or C.sub.1-6 alkyl. X is O, S or NR.sup.4. Y is an aryl ring system having 6-10 ring members or a heteroaryl ring system having 5-10 ring members where 1-3 ring members are each N, O or S. Subscript n is 1 or 2. The compounds also include salts, hydrates and isomers of the compounds of the present invention.
Inventor(s): Ellies; Debra (Parkville, MO), Rosenberg; William (Overland Park Drive, KS)
Assignee: Osteogenex Inc. (Kansas City, KS)
Application Number:12/472,134
Patent Claims:see list of patent claims

Details for Patent 8,080,575

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Amgen PROLIA denosumab INJECTABLE; SUBCUTANEOUS 125320 001 2010-06-01   Try a Free Trial Osteogenex Inc. (Kansas City, KS) 2028-05-29 RX Orphan search
Amgen XGEVA denosumab INJECTABLE; SUBCUTANEOUS 125320 002 2010-06-01   Try a Free Trial Osteogenex Inc. (Kansas City, KS) 2028-05-29 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Department of Justice
Boehringer Ingelheim
Daiichi Sankyo
Chinese Patent Office

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.